HS-001
Systolic Heart Failure (HFrEF) including Dilated Cardiomyopathy (DCM), Old Myocardial Infarction (OMI), Dilated-phase Hypertrophic Cardiomyopathy (D-HCM)
Phase 1Active (Planned initiation 2021)
Key Facts
Indication
Systolic Heart Failure (HFrEF) including Dilated Cardiomyopathy (DCM), Old Myocardial Infarction (OMI), Dilated-phase Hypertrophic Cardiomyopathy (D-HCM)
Phase
Phase 1
Status
Active (Planned initiation 2021)
Company
About Heartseed
A Japanese biotech developing iPSC-derived cardiomyocyte transplantation therapies to remuscularize the heart and treat severe heart failure.
View full company profile